关注心血管疾病防治,关爱医师身心健康!“心随绿动”雅培健心公益定向赛苏州开跑

2019-08-30 佚名 生物探索

2019年8月29日,在中华医学会第十五次全国检验医学学术会议开幕当天,由雅培发起的“心随绿动”健心公益定向赛在苏州热力开跑。

2019年8月29日,在中华医学会第十五次全国检验医学学术会议开幕当天,由雅培发起的“心随绿动”健心公益定向赛在苏州热力开跑。现场两百余名来自全国的检验科医师齐聚苏州国际博览中心,一起用双脚丈量美丽的金鸡湖畔,倡导大众共同关注心血管健康,关爱医师的身心健康。



雅培“心随绿动”健心公益定向赛开赛仪式

心脏健康,医者先行

目前,心血管疾病已成为严重威胁国民健康的首要病因。数据显示,我国心血管病患者人数为2.9亿,且死亡率高居首位, 占疾病死亡构成的40%以上 。为遏制心血管疾病发病率的持续上升态势,国务院近期印发《国务院关于实施健康中国行动的意见》中,把心脑血管疾病防治列入重大行动之一,并明确倡导全民健身、定期体检(35岁以上人群)等健康管理,以此来降低心血管病的患病风险。

因此,值中华医学会第十五次全国检验医学学术会议召开之际,雅培发起了“心脏健康,医者先行”的倡议,通过举办健心公益定向赛,鼓励检验科医师身体力行,积极运动,做好自身的心血管疾病预防和健康管理,更好地作为心血管疾病的前沿“侦察兵”,守护大众的心脏健康。

“每一个心血管病医疗决策的背后,都离不开检验科为其提供精确、快速、可靠的诊断信息。随着老龄化及各类疾病发病率的不断攀升,医院检验科时常面临高负荷的工作,我国检验医师的总体健康状况同样值得引起关注。” 中国人民解放军总医院临床检验科主任、中华医学会检验分会主任委员王成彬教授表示:“很高兴看到雅培举办此次活动,不仅让广大检验医师在紧张的会议行程之余,重拾身心健康和活力,还在活动中帮助医师强化心脏疾病诊断相关知识及纠正常见误区。”



中国人民解放军总医院临床检验科主任、中华医学会检验分会主任委员王成彬教授于开赛仪式上致辞

本次公益定向赛将“有氧运动”与“趣味科普”巧妙结合,全程两公里的赛道沿途共设四个趣味打卡点,涵盖了心脏健康管理小贴士、辨识心血管疾病诊断常用标记物及其临床价值、以及更正心脏疾病诊断常见误区等。

助力临床,诊断先行

事实上,60%-70%的重大临床治疗决策都需要以检验结果为依据。尤其对于心血管疾病而言,高效、精准的检验对患者至关重要。目前,雅培在心血管疾病诊断多个领域处于领先地位,可针对心衰、心梗等疾病提供前沿诊断解决方案,也可对健康人群的心血管风险进行评估2,从而改善心血管疾病防控局面。

针对心脏急危重症患者,雅培可提供快速诊断和预后判断,帮助患者获得有效的治疗。以高敏肌钙蛋白I(hs-cTnI)为例,能使心肌梗死的诊断时间从三小时缩减至一小时,有效缓解急诊滞留的现象,为挽救患者生命争取时间。此外,该标记物还提供了男女差异参考范围,大大提高了女性心梗的检出率。

对于健康人群,通过早期识别和干预,可降低疾病发病,节省医疗成本。传统的心血管风险评估因素包括血压、血脂、年龄、家族史、地区等因素,而作为首个在具有CE认证国家获批用于心血管风险评估的标志物,雅培高敏肌钙蛋白I创新性地开拓了心肌标记物的应用领域。

雅培中国诊断产品部门业务副总裁陈健忠表示:“作为全球体外诊断领域的领导者,雅培希望借此次健心公益定向赛的发起,呼吁广大检验科医师关注自己的身心健康,同时也倡导人们提高对心血管疾病的防治意识,鼓励大家用健康的生活方式,活出精彩人生。在未来,我们也将继续积极响应政府的号召,致力于以最新前沿科技惠及更多心血管疾病患者,为‘健康中国’的建设添砖加瓦。”

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1770898, encodeId=6de41e708981c, content=<a href='/topic/show?id=3a5b300654c' target=_blank style='color:#2F92EE;'>#关爱#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30065, encryptionId=3a5b300654c, topicName=关爱)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a0a38187382, createdName=jklm22, createdTime=Sun Jul 19 08:19:00 CST 2020, time=2020-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1769061, encodeId=3baf1e69061fa, content=<a href='/topic/show?id=d7674593e05' target=_blank style='color:#2F92EE;'>#定向#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45937, encryptionId=d7674593e05, topicName=定向)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=920637977772, createdName=liao1632, createdTime=Sat Nov 30 02:19:00 CST 2019, time=2019-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2037446, encodeId=cbdb203e4466d, content=<a href='/topic/show?id=66f49322993' target=_blank style='color:#2F92EE;'>#身心健康#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93229, encryptionId=66f49322993, topicName=身心健康)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=232a2500033, createdName=1249859em38(暂无昵称), createdTime=Sun May 03 02:19:00 CST 2020, time=2020-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498619, encodeId=b9981498619f9, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Sun Sep 01 00:19:00 CST 2019, time=2019-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1579918, encodeId=44d915e99181e, content=<a href='/topic/show?id=0ebc98e077a' target=_blank style='color:#2F92EE;'>#雅培#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98707, encryptionId=0ebc98e077a, topicName=雅培)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80e616567008, createdName=12498877m103暂无昵称, createdTime=Sun Sep 01 00:19:00 CST 2019, time=2019-09-01, status=1, ipAttribution=)]
    2020-07-19 jklm22
  2. [GetPortalCommentsPageByObjectIdResponse(id=1770898, encodeId=6de41e708981c, content=<a href='/topic/show?id=3a5b300654c' target=_blank style='color:#2F92EE;'>#关爱#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30065, encryptionId=3a5b300654c, topicName=关爱)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a0a38187382, createdName=jklm22, createdTime=Sun Jul 19 08:19:00 CST 2020, time=2020-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1769061, encodeId=3baf1e69061fa, content=<a href='/topic/show?id=d7674593e05' target=_blank style='color:#2F92EE;'>#定向#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45937, encryptionId=d7674593e05, topicName=定向)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=920637977772, createdName=liao1632, createdTime=Sat Nov 30 02:19:00 CST 2019, time=2019-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2037446, encodeId=cbdb203e4466d, content=<a href='/topic/show?id=66f49322993' target=_blank style='color:#2F92EE;'>#身心健康#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93229, encryptionId=66f49322993, topicName=身心健康)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=232a2500033, createdName=1249859em38(暂无昵称), createdTime=Sun May 03 02:19:00 CST 2020, time=2020-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498619, encodeId=b9981498619f9, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Sun Sep 01 00:19:00 CST 2019, time=2019-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1579918, encodeId=44d915e99181e, content=<a href='/topic/show?id=0ebc98e077a' target=_blank style='color:#2F92EE;'>#雅培#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98707, encryptionId=0ebc98e077a, topicName=雅培)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80e616567008, createdName=12498877m103暂无昵称, createdTime=Sun Sep 01 00:19:00 CST 2019, time=2019-09-01, status=1, ipAttribution=)]
    2019-11-30 liao1632
  3. [GetPortalCommentsPageByObjectIdResponse(id=1770898, encodeId=6de41e708981c, content=<a href='/topic/show?id=3a5b300654c' target=_blank style='color:#2F92EE;'>#关爱#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30065, encryptionId=3a5b300654c, topicName=关爱)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a0a38187382, createdName=jklm22, createdTime=Sun Jul 19 08:19:00 CST 2020, time=2020-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1769061, encodeId=3baf1e69061fa, content=<a href='/topic/show?id=d7674593e05' target=_blank style='color:#2F92EE;'>#定向#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45937, encryptionId=d7674593e05, topicName=定向)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=920637977772, createdName=liao1632, createdTime=Sat Nov 30 02:19:00 CST 2019, time=2019-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2037446, encodeId=cbdb203e4466d, content=<a href='/topic/show?id=66f49322993' target=_blank style='color:#2F92EE;'>#身心健康#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93229, encryptionId=66f49322993, topicName=身心健康)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=232a2500033, createdName=1249859em38(暂无昵称), createdTime=Sun May 03 02:19:00 CST 2020, time=2020-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498619, encodeId=b9981498619f9, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Sun Sep 01 00:19:00 CST 2019, time=2019-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1579918, encodeId=44d915e99181e, content=<a href='/topic/show?id=0ebc98e077a' target=_blank style='color:#2F92EE;'>#雅培#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98707, encryptionId=0ebc98e077a, topicName=雅培)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80e616567008, createdName=12498877m103暂无昵称, createdTime=Sun Sep 01 00:19:00 CST 2019, time=2019-09-01, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1770898, encodeId=6de41e708981c, content=<a href='/topic/show?id=3a5b300654c' target=_blank style='color:#2F92EE;'>#关爱#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30065, encryptionId=3a5b300654c, topicName=关爱)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a0a38187382, createdName=jklm22, createdTime=Sun Jul 19 08:19:00 CST 2020, time=2020-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1769061, encodeId=3baf1e69061fa, content=<a href='/topic/show?id=d7674593e05' target=_blank style='color:#2F92EE;'>#定向#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45937, encryptionId=d7674593e05, topicName=定向)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=920637977772, createdName=liao1632, createdTime=Sat Nov 30 02:19:00 CST 2019, time=2019-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2037446, encodeId=cbdb203e4466d, content=<a href='/topic/show?id=66f49322993' target=_blank style='color:#2F92EE;'>#身心健康#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93229, encryptionId=66f49322993, topicName=身心健康)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=232a2500033, createdName=1249859em38(暂无昵称), createdTime=Sun May 03 02:19:00 CST 2020, time=2020-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498619, encodeId=b9981498619f9, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Sun Sep 01 00:19:00 CST 2019, time=2019-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1579918, encodeId=44d915e99181e, content=<a href='/topic/show?id=0ebc98e077a' target=_blank style='color:#2F92EE;'>#雅培#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98707, encryptionId=0ebc98e077a, topicName=雅培)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80e616567008, createdName=12498877m103暂无昵称, createdTime=Sun Sep 01 00:19:00 CST 2019, time=2019-09-01, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1770898, encodeId=6de41e708981c, content=<a href='/topic/show?id=3a5b300654c' target=_blank style='color:#2F92EE;'>#关爱#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30065, encryptionId=3a5b300654c, topicName=关爱)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a0a38187382, createdName=jklm22, createdTime=Sun Jul 19 08:19:00 CST 2020, time=2020-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1769061, encodeId=3baf1e69061fa, content=<a href='/topic/show?id=d7674593e05' target=_blank style='color:#2F92EE;'>#定向#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45937, encryptionId=d7674593e05, topicName=定向)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=920637977772, createdName=liao1632, createdTime=Sat Nov 30 02:19:00 CST 2019, time=2019-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2037446, encodeId=cbdb203e4466d, content=<a href='/topic/show?id=66f49322993' target=_blank style='color:#2F92EE;'>#身心健康#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93229, encryptionId=66f49322993, topicName=身心健康)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=232a2500033, createdName=1249859em38(暂无昵称), createdTime=Sun May 03 02:19:00 CST 2020, time=2020-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498619, encodeId=b9981498619f9, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Sun Sep 01 00:19:00 CST 2019, time=2019-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1579918, encodeId=44d915e99181e, content=<a href='/topic/show?id=0ebc98e077a' target=_blank style='color:#2F92EE;'>#雅培#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98707, encryptionId=0ebc98e077a, topicName=雅培)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80e616567008, createdName=12498877m103暂无昵称, createdTime=Sun Sep 01 00:19:00 CST 2019, time=2019-09-01, status=1, ipAttribution=)]

相关资讯

雅培制药将以**4.95亿美元购俄罗斯药厂VEROPHARM

美国医疗保健企业雅培制药周二表示,将最多以4.95亿美元收购俄罗斯药厂Veropharm; 雅培制药在俄罗斯运营近40年,终于在俄罗斯有了自己的制药厂。 由于俄罗斯经济蹒跚及乌克兰危机,今年俄罗斯境内的企业并购活动乏善可陈。美国企业对俄罗斯的投资尤其受阻,美国政府5月时建议企业高管不要参加俄罗斯举行的一大型投资论坛。 据汤森路透数据,雅培制药收购案是菲利普莫里斯及日本烟草去年12月宣布收购

雅培生命旗下丙肝复方药物获FDA突破性治疗药物资格

5月6日,雅培生命表示美国食品药品管理局(FDA)授予其抗丙肝病毒复方药物突破性治疗药物资格,该资格的获得将有助于加快这一复方药物的审评进度,或许还能缩短其临床试验过程。 雅培生命的这款复方药物由ABT-450/r(蛋白酶抑制剂和利托那韦)、ABT-267(NS5A抑制剂)和ABT-333(非核苷聚合酶抑制剂)组成,此外还可加或不加利巴韦林。其突破性治疗药物资格是紧继吉利德的Sofosbuvir

雅培阿达木单抗(Humira)获欧盟批准用于放射学阴性中轴脊柱关节炎(nr-axSpA)

雅培(Abbott)宣布,欧盟委员会(EC)已批准阿达木单抗(Humira)用于放射学阴性中轴脊柱关节炎(Non-radiographic Axial Spondyloarthritis,nr-axSpA)成人患者的治疗,Humira是首个也是唯一一个获批用于治疗这一疾病的药物。 该适应症的获批,使Humira自2003年首次推出以来,在欧盟的适应症达到了8种之多。 活动性中轴性脊柱关节炎(A

雅培推出世界**可吸收血管支架

雅培(Abbott)将在欧洲、亚太部分地区及拉丁美洲推出世界首款药物洗脱生物可吸收血管支架(drug eluting bioresorbable vascular scaffold,BVS)——Absorb,该支架的推出,有望对冠状动脉疾病(CAD)的治疗产生革命性的改变。 Absorb是首个生物可吸收药物洗脱支架,其工作原理与金属支架相似,即通过恢复血流量发挥作用,用于治疗冠状动脉疾病(CAD

雅培(Abbott)公司Absolute Pro®支架系统获FDA批准

2012年3月7日,雅培(Abbott)公司今天宣布,FDA批准其Absolute Pro血管自膨式支架系统(Absolute Pro? Vascular Self-Expanding Stent System)用于髂总动脉疾病(iliac artery disease)的治疗,这是一种周边动脉疾病(peripheral artery disease,PAD),能影响患者的双下肢。 随着时间的推

FDA批准雅培HCV基因型检测试剂盒上市

  2013年6月20日,美国食品与药物管理局(FDA)批准了可检测到患者携带的丙型肝炎病毒(HCV)基因型的试剂盒(Abbott RealTime HCV Genotype II)上市,该试剂盒可对感染者的血清或血浆标本鉴别出基因型1、1a、1b、2、3、4和5。 该检测方法获准用于已知的HCV慢性感染者的鉴别诊断,而不用于血液遗传物质、血制品或组织供者的